Filing Flows › Industries › Health Care › Wholesale-Drugs, Proprietaries & Druggists' Sundries
Wholesale-Drugs, Proprietaries & Druggists' Sundries SIC 5122
10 companies filing with the SEC under SIC 5122. Median revenue growth -2% year on year in Q2 2026 (middle half -32% to +6%, 8 companies). The growth model expects the industry's combined revenue to grow +9% in Q3 2026. 56 customer or supplier links named in annual reports.
Money flow: where the industry's revenue goes
Drawn in the browser: an estimate of where the industry's revenue goes — what it buys from other industries, the pay that reaches households, taxes and profit — beside its filed cash flow, two tiers of suppliers and its capital spending by kind of asset.
Open the industry: growth distribution, money flow, network →
Who sells to whom
Customers and suppliers named in the companies' annual reports; the share is of the supplier's revenue.
- MCK → CVS 24% of the supplier's revenue, $96.8B
- COR → Walgreens and Boots UK Ltd 25% of the supplier's revenue, $80.3B
- CAH → CVS 30% of the supplier's revenue, $66.8B
- COR → CI 13% of the supplier's revenue, $41.8B
- BMY → MCK 36% of the supplier's revenue, $17.3B
- PFE → MCK 25% of the supplier's revenue, $15.6B
- BMY → COR 29% of the supplier's revenue, $14.0B
- AMGN → MCK 34% of the supplier's revenue, $12.5B
- BMY → CAH 22% of the supplier's revenue, $10.6B
- PFE → COR 16% of the supplier's revenue, $10.0B
- AMGN → COR 27% of the supplier's revenue, $9.9B
- PFE → CAH 13% of the supplier's revenue, $8.1B
- AMGN → CAH 16% of the supplier's revenue, $5.9B
- BHC → COR 18% of the supplier's revenue, $1.8B
- BHC → MCK 16% of the supplier's revenue, $1.6B
- BHC → CAH 14% of the supplier's revenue, $1.4B
- ONC → MCK 18% of the supplier's revenue, $935M
- Keenova Therapeutics plc → COR 48% of the supplier's revenue, $680M
- ELAN → COR 12% of the supplier's revenue, $566M
- ALKS → MCK 38% of the supplier's revenue, $561M
- BLCO → MCK 10% of the supplier's revenue, $510M
- BLCO → CAH 10% of the supplier's revenue, $510M
- JAZZ → MCK 10% of the supplier's revenue, $427M
- EXEL → CAH 12% of the supplier's revenue, $278M
- ALKS → COR 18% of the supplier's revenue, $266M
Growth model
Industry revenue, the same companies year on year; 80% ranges. Fitted on SEC filings and tested out of sample (how).
| Quarter | Growth Y/Y | Revenue | 80% range |
|---|---|---|---|
| Q3 2026 | +8.7% | $274.5B | $265.8B – $283.2B |
| Q4 2026 | +9.8% | $284.9B | $274.7B – $295.1B |
| Q1 2027 | +10.2% | $261.5B | $251.9B – $271.2B |
| Q2 2027 | +10.2% | $211.4B | $203.6B – $219.3B |
Capital spending and supply chain →
Companies
| Company | Quarterly revenue | Y/Y | Stage |
|---|---|---|---|
| MCK McKesson | $111.0B | +8% | mature |
| COR Cencora | $84.8B | +5% | mature |
| CAH Cardinal Health | $67.5B | — | deceleration |
| HLF Herbalife | $1.4B | +5% | mature |
| NUS Nu Skin Enterprises | $311M | -17% | contraction |
| COSM Cosmos Health | $19.0M | +29% | transition |
| MEDS DataMeds AI | $1.8M | -77% | transition |
| STEK Stemtech | $629K | -10% | mature |
| ESYN HWH International | $64K | -79% | contraction |
| Essence Array | $5K | — | — |
Growth from positive, comparable quarterly revenue as filed; industries are SEC Standard Industrial Classification codes. Data Nov 8, 2026.